Drugs / Sutezolid
Sutezolid
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00990990 | Oct 2009 → May 2010 | tuberculosis | Sequella, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00871949 | Apr → Aug 2009 | tuberculosis | Sequella, Inc. | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT06192160 | Mar 2025 → Nov 2026 expected | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT05971602 | Jul 2023 → Feb 2025 | pulmonary tuberculosis | Gates Medical Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03959566 | May 2021 → Sep 2022 | pulmonary tuberculosis | Michael Hoelscher | Completed | Met primary |
| Phase 2 | NCT01225640 | Aug → Dec 2011 | tuberculosis | Sequella, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05686356 | Jul 2023 → Jan 2026 overdue | tuberculosis | The Aurum Institute NPC | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03237182 | Jun 2017 → Dec 2022 | multidrug-resistant tuberculosis | Centre for the AIDS Programme of Research in South Africa | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03199313 Comparator | Sep → Dec 2017 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-07-17 | Sequella, Inc. | Sequella Acquires Exclusive Worldwide Rights to Pfizer's Sutezolid, Currently in Clinical Development for Tuberculosis sequella.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sutezolid | “Sutezolid (PNU-100480) is a linezolid analog with superior bactericidal activity against Mycobacterium tuberculosis in the hollow fiber, whole blood and mouse models.” PMID 24732289 ↗ Apr 20146“linezolid, sutezolid, clofazimine, bedaquiline” NCT03237182 ↗ |
| Known as | NSC-742407 | ChEMBL registry synonym — accepted as the source's own label CHEMBL288149 ↗ |
| Known as | Oxazolidininone | ChEMBL registry synonym — accepted as the source's own label CHEMBL288149 ↗ |
| Known as | PF-02341272 | “A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PNU-100480 (PF-02341272) After First Time Administration Of Ascending Oral Doses To Healthy Adult...” NCT00871949 ↗1“PNU-100480 (PF-02341272) After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects” NCT00990990 ↗ |
| Known as | PNU-100480 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00990990 ↗ |
| Known as | U 100480 | ChEMBL registry synonym — accepted as the source's own label CHEMBL288149 ↗ |
| Known as | U-480 | ChEMBL registry synonym — accepted as the source's own label CHEMBL288149 ↗ |
| Modality | Small molecule | “The oxazolidinone PNU-100480 is superior to linezolid against experimental murine tuberculosis.” PMID 20629533 ↗ Sep 2010 |
| Route | Oral | “Nineteen healthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.” PMID 20629533 ↗ Sep 2010 |